# Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

> **NCT01518153** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- Leukemia
- Lymphoma
- Myeloma
- Myeloproliferative Diseases

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Melphalan
- **DRUG:** Alemtuzumab
- **PROCEDURE:** Stem Cell Infusion
- **DRUG:** Tacrolimus
- **DRUG:** Methotrexate
- **DRUG:** G-CSF
- **PROCEDURE:** Low Dose Donor T-Cells
- **PROCEDURE:** High Dose Donor T-Cells

## Key facts

- **NCT ID:** NCT01518153
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-02
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Objectives not met.
- **Last updated:** 2016-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01518153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01518153, "Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01518153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*